- Home
- BGI vs BFRI Comparison
BGI vs BFRI Comparison
Compare BGI & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGI | BFRI |
|---|---|---|
| Founded | 1879 | 1997 |
| Country | Canada | United States |
| Employees | N/A | 94 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 13.2M |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | BGI | BFRI |
|---|---|---|
| Price | $0.68 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.75 |
| AVG Volume (30 Days) | 21.5K | ★ 121.5K |
| Earning Date | 12-05-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | N/A | $16.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.54 |
| 52 Week High | $1.57 | $1.19 |
Technical Indicators
Market Signals| Indicator | BGI | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 40.35 | 64.13 |
| Support Level | $0.64 | $0.79 |
| Resistance Level | $0.78 | $1.17 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 25.20 | 73.68 |
Price Performance
Historical ComparisonAbout BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.